ClinicalTrials.gg
CompletedNCT03341910Updated Aug 17, 2020Results posted

A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris

A Phase 2 interventional study of DFD-03 Lotion, 0.1% and Tazorac Cream, 0.1% in Acne Vulgaris, sponsored by Dr. Reddy's Laboratories Limited. Completed at 1 site in United States. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2020-08-17.

Sponsored by Dr. Reddy's Laboratories Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
9 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 374 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.

Enrollment
138th of 354
155 · median 78
Started
2017
with 22 others
Phase 2
65 of 374
none open now
Registered
239th of 374
by date

Among the 374 studies in Acne Vulgaris with a site in United States, this one is the 138th largest by enrollment of the 354 interventional ones that give a count, is one of 23 that started in 2017, is one of 65 in phase 2, and was the 239th registered.

Acne Vulgaris

795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

20 of the 374 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 9 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies in Acne Vulgaris with a site in United States, or all of them as a file.
02

Study summary

A study for Subjects with mild to moderate facial acne vulgaris. During the 12-week treatment period subjects randomized to DFD-03 Lotion or Vehicle Lotion will use the study drug twice daily. Subjects randomized to Tazorac Cream or Vehicle Cream will use the study drug once daily in the evening. Safety assessments will include the investigator's assessment of local cutaneous tolerance/application site reactions on the face, vital signs and adverse events.

Read the detailed description

A study for Subjects with mild to moderate facial acne vulgaris. Subjects will be randomized to treatment with either DFD-03 (tazarotene) Lotion 0.1%, Tazorac (tazarotene) Cream, 0.1%, Vehicle Lotion or Vehicle Cream. During the 12-week treatment period subjects randomized to DFD-03 Lotion or Vehicle Lotion will use the study drug twice daily. Subjects randomized to Tazorac Cream or Vehicle Cream will use the study drug once daily in the evening. Subjects will be instructed to treat the entire face.

Safety assessments will include the investigator's assessment of local cutaneous tolerance/application site reactions on the face, vital signs and adverse events. Urine pregnancy tests will be performed for all female subjects. A physical examination will be performed.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
9 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be at least 12 years of age. At selected site(s), a total of approximately eight subjects 9-11 years of age will be enrolled into the 2 arms of DFD-03 lotion group (active and vehicle).
  2. A clinical diagnosis of facial acne vulgaris with a facial Investigator's Global Assessment (IGA) score of 2 (mild) to 3 (moderate) at Baseline. At selected site(s), up to twelve subjects with acne lesions on the chest and/or back (including shoulders) in addition to those on the face will treat their chest and/or back (including shoulders) in addition to their face.
  3. Inflammatory lesion count (papules and pustules) of at least 20, non-inflammatory lesion count (closed and open comedones) of at least 25 on the face including the nose, and no more than 2 nodulocystic lesions. This criteria is not applicable to the 9-11 years age group as long as subjects have an IGA score of 2 (mild) to 3 (moderate) at Baseline.
  4. Females, regardless of : Must have a negative urine pregnancy test and if sexually active, must be on or use an acceptable method of .
  5. Subjects agree not to use any product on the face during the entire course of study except for non-medicated, investigator-approved cleanser, sunscreen, face wash, and make-up as instructed by the investigator.
  6. Subjects must be willing to comply with sun avoidance measures for the face, including use of investigator-approved sunscreen and/or hats, have limited sun exposure time, and have no tanning bed use.
  7. Subject must be in good general health as determined by the investigator and supported by the medical history, physical examination and vital signs.

Exclusion criteria

Exclusion Criteria:

  1. Females who are pregnant or lactating or planning to become pregnant during the study period.
  2. Treatment with the following products:

    Topical acne treatments or other topical facial medication in the 14 days prior to Baseline Systemic and systemic acne treatments in the 30 days prior to Baseline Systemic retinoid use in the 180 days prior to Baseline Undertaken certain facial procedures such as chemical peel, laser treatment, photodynamic therapy, acne surgery, cryodestruction or chemodestruction, x-ray therapy, intralesional steroids, dermabrasion, or depilation (except eyebrow shaping) in 30 days prior to Baseline.

    Treatment with a medication or procedure that, in the opinion of the investigator, would put the subject at unacceptable risk for participation in the study or may interfere with evaluations in the study.

    Treatment with an product or device in 30 days prior to Baseline.

  3. Known allergic reaction to retinoids or tazarotene or any of the product ingredients.
  4. Presence of any facial skin disease or condition that would interfere with the study or place the subject at unacceptable risk including sunburn, rosacea, seborrheic dermatitis, perioral dermatitis, lupus, dermatomyositis, psoriasis, eczema, squamous cell carcinoma, acneiform eruptions caused by medications, steroid acne, steroid folliculitis, bacterial folliculitis or any other facial disease or condition.
  5. Subjects with a serious and or chronic medical condition such as chronic or active liver disease, renal impairment, heart disease, severe respiratory disease, rheumatoid arthritis, current , conditions, or any other disease that, in the opinion of the investigator, would interfere with the study or place the subject at unacceptable risk.
  6. Subjects who have been treated for alcohol dependence or alcohol or drug abuse in the year.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
155 participants (actual)

Study arms

  • Experimental
    DFD-03 Lotion, 0.1%

    DFD-03 Lotion, 0.1% to be applied twice daily approximately 12 hours apart, for 1 minute and rinsed off

    Drug: DFD-03 Lotion, 0.1%

  • Active comparator
    Tazorac Cream, 0.1%

    Tazorac Cream, 0.1% to be applied once in the evening and left overnight for approximately 12 hours

    Drug: Tazorac Cream, 0.1%

  • Placebo comparator
    Vehicle Lotion

    Vehicle Lotion to be applied twice daily for 1 minute and rinsed off

    Drug: DFD-03 Vehicle Lotion 0%

  • Placebo comparator
    Vehicle Cream

    Vehicle Cream to be applied once in the evening and left overnight for approximately 12 hours

    Drug: Tazorac Vehicle Cream 0%

Interventions

  • DrugDFD-03 Lotion, 0.1%

    DFD-03 Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.

    Also known as: Tazarotene Lotion, 0.1%

  • DrugTazorac Cream, 0.1%

    Tazorac Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.

    Also known as: Tazarotene Cream, 0.1%

  • DrugDFD-03 Vehicle Lotion 0%

    Vehicle Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.

    Also known as: Vehicle Lotion 0%

  • DrugTazorac Vehicle Cream 0%

    Vehicle Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.

    Also known as: Vehicle Cream 0%

06

What researchers measure

Primary outcomes

  1. Adverse Event Occurences in DFD-03 Lotion Versus Tazorac Cream Groups

    Frequency count of treatment emergent adverse events will be compared between DFD-03 Lotion and Tazorac Cream groups.

    Time frame: Baseline to Week 12

07

Results

Posted Aug 17, 2020

Participant flow

Participant flow — Overall Study
MilestoneDFD-03 Lotion, 0.1%Tazorac Cream, 0.1%DFD-03 Vehicle LotionTazorac Vehicle Cream
Started54492626
Completed54492626
Not completed0000

Outcome measures

PrimaryAdverse Event Occurences in DFD-03 Lotion Versus Tazorac Cream Groups

Frequency count of treatment emergent adverse events will be compared between DFD-03 Lotion and Tazorac Cream groups.

Time frame:
Baseline to Week 12
Reported as:
Number · Adverse Events
Adverse Event Occurences in DFD-03 Lotion Versus Tazorac Cream Groups
Adverse EventsDFD-03 Lotion, 0.1%Tazorac Cream, 0.1%DFD-03 Vehicle LotionTazorac Vehicle Cream
Adverse Event Occurences in DFD-03 Lotion Versus Tazorac Cream Groups73811415

Adverse events

Collected over Adverse events were collected from treatment initiation until study product treatment discontinuation (approximately 12 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DFD-03 Lotion, 0.1%0/54 (0%)0/54 (0%)22/54 (40.7%)
Tazorac Cream, 0.1%0/49 (0%)0/49 (0%)26/49 (53.1%)
Vehicle Lotion0/26 (0%)0/26 (0%)9/26 (34.6%)
Vehicle Cream0/26 (0%)0/26 (0%)11/26 (42.3%)
Most frequent other events
Most frequent other events
EventDFD-03 Lotion, 0.1%Tazorac Cream, 0.1%Vehicle LotionVehicle Cream
Application site drynessGeneral disorders18/5417/492/263/26
Application Site PainGeneral disorders14/5413/491/261/26
Application site exfoliationGeneral disorders14/5412/492/263/26
Application Site ErythemaGeneral disorders8/549/491/263/26
Application Site PruritusGeneral disorders6/543/492/262/26
Viral upper respiratory tract infectionInfections and infestations1/545/492/261/26

Baseline characteristics

Safety Population - All subjects who received study product and provided any post-baseline safety information.

Age, Categorical
Age, Categorical(Participants)DFD-03 Lotion, 0.1%Tazorac Cream, 0.1%DFD-03 Vehicle LotionTazorac Vehicle CreamTotal
<=18 years201310952
Between 18 and 65 years34361617103
>=65 years00000
Age, Continuous
Age, Continuous(years)DFD-03 Lotion, 0.1%Tazorac Cream, 0.1%DFD-03 Vehicle LotionTazorac Vehicle CreamTotal
Mean21.9 ± 9.523.1 ± 8.922.0 ± 9.725.0 ± 10.522.8 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)DFD-03 Lotion, 0.1%Tazorac Cream, 0.1%DFD-03 Vehicle LotionTazorac Vehicle CreamTotal
Female2527121276
Male2922141479
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DFD-03 Lotion, 0.1%Tazorac Cream, 0.1%DFD-03 Vehicle LotionTazorac Vehicle CreamTotal
American Indian or Alaska Native00000
Asian40217
Native Hawaiian or Other Pacific Islander00101
Black or African American453618
White46442018128
More than one race00000
Unknown or Not Reported00011
Region of Enrollment
Region of Enrollment(participants)DFD-03 Lotion, 0.1%Tazorac Cream, 0.1%DFD-03 Vehicle LotionTazorac Vehicle CreamTotal
United States54492626155
08

Study locations

1 site
  • International Dermatology Inc.
    Miami, Florida 33144, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in May 2018, 8 months.

Results were first posted in Aug 2020, 2 years 2 months after primary completion. A results delay was requested in Sep 2019.

Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 8 months is below that.

Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2017
First posted
Nov 14, 2017
StartActual
Aug 21, 2017
Primary completionActual
May 18, 2018
CompletionActual
May 18, 2018
Results delay requested
Sep 24, 2019
Results first posted
Aug 17, 2020
Last update
Aug 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03341910
Responsible party
Sponsor
First posted
Nov 14, 2017
Start date
Aug 21, 2017
Primary completion
May 18, 2018
Completion
May 18, 2018
Results posted
Aug 17, 2020
Last update
Aug 17, 2020

Study contacts

Srinivas R. Sidgiddi, M.D.
study director · Dr. Reddy's Laboratories Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion